SEC Form 4 · accession 0001209191-18-012405
GENOMIC HEALTH INC · GHDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Phillip G. Febbo
Officer — Chief Medical Officer
Period of report
Feb 20, 2018
Accepted (ET)
Feb 22, 2018 · 4:19 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001131324
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3,F4 | Feb 20, 2018 | S | 4,642 | $32.8059 | D | 21,687 | D | |
| Common StockF1,F2,F5,F4 | Feb 20, 2018 | S | 300 | $33.35 | D | 21,387 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017.
- F2Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
- F3Represents weighted average sale price. Actual sale prices ranged from $32.34 to $33.32.
- F4Includes an aggregate of 21,387 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
- F5Represents weighted average sale price. Actual sale prices ranged from $33.34 to $33.36.